Search Results
Your search for ,maY matches 17173 pages
Showing 3701 - 3750Do LGBTQI+ Patients With Cancer Receive Mental Health Information Tailored to Their Needs?
Although customized health education materials for lesbian, gay, bisexual, transgender, queer, and intersex (LGBTQI+) cancer survivors may play a pivotal role in their experiences throughout their cancer care continuum, a study by Burnett et al has found that regardless of their satisfaction with...
Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs White Women With Breast Cancer
Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...
Many Families of Children With Leukemia May Experience Food Insecurity That Is Not Alleviated by Federal Assistance Program
Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced food insecurity, and almost half of the families eligible for the Supplemental Nutrition Assistance Program (SNAP) did not receive benefits. In addition, receiving SNAP ...
New Study Shows Sugar-Sweetened Drinks May Increase Risk of Cancer Mortality
In a large study led by researchers at the American Cancer Society (ACS), men and women who drank two or more servings of sugar-sweetened beverages per day had a 5% increased risk of death from an obesity-related cancer, including gastrointestinal, postmenopausal breast, endometrial, and kidney...
Novel Photon-Counting CT May Improve Myeloma Bone Disease Detection
New computed tomography (CT) technology paired with artificial intelligence (AI)-based noise reduction may offer superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT, according to a recent study published by Baffour et al in Radiology....
Reporting of Hispanic Ethnicity and Race in Breast Cancer Studies: National Cancer Database Analysis
In a National Cancer Database (NCDB) analysis reported in a research letter in JAMA Oncology, Bazan et al found that Hispanic ethnicity was reported in patient demographics or results in less than half of studies in breast cancer, with a smaller proportion categorizing race and ethnicity into...
Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma
In a phase II trial (SECOMBIT) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found that sequential immunotherapy and targeted therapy with ipilimumab/nivolumab followed at disease progression by encorafenib/binimetinib was associated with good survival...
Expert Point of View: Jacek Jassem, MD
Abstract discussant, Jacek Jassem, MD, of the Medical University of Gdansk, in Poland, underscored smoking as the most important cause of lung cancer, noting that between 85% and 90% of patients with lung cancer are current or former smokers. “Lung cancer screening, which has recently become...
Trends in Incidence of Cutaneous T-Cell Lymphoma in the United States
In a study reported in a research letter in JAMA Oncology, Cai et al found that the incidence of cutaneous T-cell lymphoma increased in the United States between 2000 and 2018. The study involved data from 18 Surveillance, Epidemiology, and End Results (SEER) Program registries for 2000 to 2018. A...
Association of Neurofilament Light Chain Levels With ICANS Risk After CAR T-Cell Therapy
In a retrospective study reported in JAMA Oncology, Butt et al found significantly higher pretreatment neurofilament light chain levels in patients who did vs did not develop immune effector cell–associated neurotoxicity syndrome (ICANS) after CD19 chimeric antigen receptor (CAR) T-cell therapy....
Study Explores Link Between Use of Antipsychotic Agents and Increased Breast Cancer Risk
A research team from the Centre for Safe Medication Practice and Research (CSMPR) in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKUMed) conducted a systematic review and meta-analysis of observational studies with over 2 million individuals and estimated a moderate...
Neil D. Gross, MD, on Cutaneous Squamous Cell Carcinoma: Recent Findings on Cemiplimab
Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectable cutaneous squamous cell carcinoma is active and may enable function-preserving surgery in some...
5-Year Outcomes With Adjuvant mFOLFIRINOX vs Gemcitabine in Pancreatic Cancer
As reported in JAMA Oncology by Thierry Conroy, MD, and colleagues, 5-year analysis of the phase III PRODIGE 24/Canadian Cancer Trials Group PA6 trial has shown a significant benefit in overall survival and other outcomes with adjuvant mFOLFIRINOX (modified oxaliplatin, irinotecan, leucovorin, and...
Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance
Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA...
Updated Results From the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutated NSCLC
Newly released results from the phase III ADAURA trial revealed that osimertinib yielded a 5.5-year median disease-free survival in the postsurgical treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC), and nearly three in four patients treated with adjuvant osimertinib were...
Dual Checkpoint Inhibitor Blockade as First-Line or Salvage Therapy for Patients With Advanced Merkel Cell Carcinoma
Merkel cell carcinoma has a high rate of metastasis and poor patient outcomes. The current standard of care for patients with recurrent, unresectable, or metastatic disease is immune checkpoint inhibitor monotherapy targeting PD-1 and PD-L1, but only about half of patients respond to this therapy....
FRESCO-2: Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer
Researchers reported study results showing that fruquintinib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR), significantly improved overall survival and progression-free survival in patients with refractory metastatic colorectal cancer. Findings...
Updated Results From the KRYSTAL-1 Study of Adagrasib in Advanced KRAS G12C–Mutated Colorectal Cancer
Updated results from KRYSTAL-1, a multicohort phase I/II study, evaluating adagrasib—an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS G12C—with or without cetuximab in patients with advanced colorectal cancer harboring a KRAS G12C mutation were presented by...
Research Explores Multicancer Early Detection Blood Testing
Physicians, care providers, and payers may be preparing for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accuracy of multicancer early detection blood testing, presented by Deb Schrag, MD, FASCO, MPH, at the...
Ana Oaknin, MD, PhD, on Cervical Cancer: Safety and Efficacy Results With Nivolumab and Ipilimumab
Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in combination with ipilimumab may provide durable tumor regression with manageable toxicity in patients...
PRESTO: Treatment Beyond Androgen-Deprivation Therapy for Relapsed Patients With High-Risk Prostate Cancer
Aggarwal et al presented data from PRESTO (AFT-19) at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA63), the first trial to evaluate whether intensifying treatment beyond androgen-deprivation therapy (ADT) by adding apalutamide with or without abiraterone acetate plus...
COSMIC-313: Cabozantinib, Nivolumab, and Ipilimumab in Previously Untreated Patients With Advanced Renal Cell Carcinoma
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by Toni K. Choueiri, MD. Dr. Choueiri, who is the Director of the Lank Center for Genitourinary Cancer at...
PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma
The ECOG-ACRIN Cancer Research Group presented data from PROSPER RCC (EA8143), the first randomized phase III trial of neoadjuvant immunotherapy in patients with kidney cancer, at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA67). Patients with high-risk renal cell...
Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the development of novel therapies, according to late-breaking data reported by Charles Swanton, MBBS, ...
ESMO and EONS Announce Launch of PrEvCan
On September 9, the European Society for Medical Oncology (ESMO), together with the European Oncology Nursing Society (EONS), announced the launch of the Europe-wide “Cancer Prevention Across Europe” campaign (PrEvCan) aimed at reducing the burden of cancer. The announcement was made at the opening ...
EQRx Pricing Strategy: Not a Win for Everyone but a Key First Step to Expand Access to Cancer Care
EQRx is an economics professor’s dream company. It is the perfect example of the principle of substitution. EQRx provides quality, lower-cost drugs in high-cost categories that may substitute for the higher-priced options. Although the profit margin for each drug unit is smaller than the...
How EQRx Aims to Reengineer the Health-Care System to Produce More Effective, Less Costly Cancer Drugs
The numbers are dizzying. The costs of cancer care in the United States are rising so fast that by 2030, it is projected the national cancer-attributable costs will total more than $246 billion, up from $183 billion in 2015—a 34% increase.1 And although the total global economic burden of cancer is ...
Association of Community Cancer Centers Announces 2022 Innovator Award Winner, Ochsner Cancer Institute
The Association of Community Cancer Centers (ACCC) recently announced that Ochsner Cancer Institute in New Orleans is a recipient of a 2022 ACCC Innovator Award. The award recognizes Ochsner Cancer Institute’s Chemotherapy Care Companion program—a digital technology system that allows the cancer...
Neurosurgeon Ashish Shah, MD, Returns to Sylvester to Head Clinical Trials and Translational Research on Brain Tumors
Ashish Shah, MD, has assumed the newly created position of Director of Clinical Trials and Translational Research and principal investigator in the Section of Virology and Immunotherapy at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative (BTI) at the University of Miami Miller School ...
ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing
ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic...
Companion Diagnostic to Identify Patients With Endometrial Cancer Eligible for Pembrolizumab Therapy Approved by the FDA
On August 11, 2022, Roche announced the U.S. Food and Drug Administration (FDA) approval of a label expansion for the Ventana MMR RxDx Panel. The Ventana MMR RxDx Panel is the first immunohistochemistry companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA ...
Researchers Find DOPA May Protect Against Melanoma and Identify Potential New Therapeutic Targets to Treat Melanoma
People with light skin tones are far more likely to develop melanoma than people with darker skin tones. This large disparity results from far more than can be explained by the ultraviolet (UV) protective effects of melanin pigment, owing in large part to the melanin precursor...
Report Finds Cancers in Adults Younger Than Age 50 Are on the Rise Globally
Over recent decades, more and more adults under the age of 50 are developing cancer. A recently published study revealed that the incidence of early-onset cancers (those diagnosed before age 50)—including breast, colon, esophageal, kidney, liver, and pancreatic cancers, among others—has...
Study Examines Efficacy of T-Cell Redirection Therapies for Patients With Relapsed Multiple Myeloma
Mount Sinai researchers have published results that show alternate therapeutic options for patients with multiple myeloma after first-line treatment with bispecific antibodies fails. While new T cell–based immunotherapies, or “T-cell redirection” therapies, such as chimeric antigen receptor (CAR)...
Sacituzumab Govitecan in Pretreated Patients With Hormone Receptor–Positive, HER2-Negative Endocrine-Resistant Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by Hope S. Rugo, MD, FASCO, and colleagues, the phase III TROPiCS-02 trial has shown a significant progression-free survival benefit with sacituzumab govitecan-hziy vs chemotherapy in previously treated patients with hormone receptor (HR)-positive,...
Wall Street Doesn’t Believe in This Target
March 2, 2009. Just published in the Journal of Clinical Investigation.1 And we even got the cover. Twists and turns of heat shock protein-90 (Hsp90), the chaperone, the evolutionary capacitor. Great name and important cancer target. People smiled when I talked about this at the Hsp90 conference....
V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, the ‘Father of Tamoxifen,’ Recounts a Life of Adventure and Science
In 2019, Her Majesty Queen Elizabeth II appointed V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, Companion of the Most Distinguished order of St. Michael and St. George (CMG), honoring his extraordinary scientific work in the development of selective estrogen receptor modulators, most notably...
Postmarketing Colitis Cases May Be Associated With Alpelisib Use
In a research letter in JAMA Oncology, Sullivan et al described details of postmarketing cases of noninfectious colitis in patients with breast cancer reported to the U.S. Food and Drug Administration that were considered possibly or probably related to alpelisib treatment. Key Findings A total of...
Report Finds 'Batwing' Mastopexy May Enable More Women to Undergo Nipple-Sparing Mastectomy
Nipple-sparing techniques can provide better outcomes for women undergoing breast reconstruction after mastectomy, but due to complication risks, these approaches are often not offered to women with sagging or larger breasts. For this group of patients, a “batwing” incision may provide a safer...
Is PD-L1 Expression a Good Predictor of Survival Benefit in Patients With Advanced Gastroesophageal Cancer Treated With Immunotherapy?
In a systematic review and meta-analysis of phase III trials of immune checkpoint inhibitor treatment in patients with advanced gastroesophageal cancer reported in JAMA Oncology, Harry H. Yoon, MD, MS, and colleagues found that PD-L1 expression was the strongest predictor of overall survival...
Fertility Preservation Procedures at Breast Cancer Diagnosis: Risk of Relapse and Disease-Specific Mortality
In a Swedish nationwide prospective cohort study reported in JAMA Oncology, Marklund et al found no increased risk of relapse or disease-specific mortality among women undergoing fertility preservation with or without hormonal stimulation at the time of breast cancer diagnosis. Study Details The...
Long-Term Findings of Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Deek et al, long-term follow-up of the pooled phase II STOMP and ORIOLE trials suggest maintained benefit of metastasis-directed therapy vs observation in patients with oligometastatic castration-sensitive prostate cancer. Study Details As noted by ...
FDA Approves Durvalumab-Based Combination for Locally Advanced or Metastatic Biliary Tract Cancer
On September 2, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer. TOPAZ-1 Efficacy was evaluated in TOPAZ-1 (ClinicalTrials.gov identifier:...
Two New Studies Find Aggressive Prostate Cancer May Be Linked to Ancestral Heritage
Two studies published simultaneously by Jaratlerdsiri et al in Nature and Gong et al in Genome Medicine have identified genetic signatures explaining ethnic differences in the severity of prostate cancer, particularly in sub-Saharan Africa. Through genetic sequencing of prostate cancer tumors from...
Study Examines How Genetic Mutations May Contribute to the Development of Cholangiocarcinoma
A team of researchers from the University of Rochester discovered how certain genetic mutations fuel the growth of cholangiocarcinoma, a rare but aggressive type of malignancy that has been on the rise in the United States. Their work, published by Guo et al in Cell Reports this week, details the...
New Risk Stratification System for Completely Resected Stage II or III Colorectal Cancer
As reported in The Lancet Oncology, Kleppe et al have developed a risk stratification system using the DoMore-v1-CRC marker and pathologic staging markers that may permit many patients with stage II or III colorectal cancer to avoid adjuvant chemotherapy. As stated by the investigators, “The...
Durability of Responses to BCMA CAR T-Cell Therapy in Patients With Multiple Myeloma May Depend on Specific Components of the Tumor Microenvironment
Currently, there are two U.S. Food and Drug Administration–approved chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) for adult patients with relapsed or refractory multiple myeloma: idecabtagene vicleucel and citacabtagene autoleucel. However, although ...
Neoadjuvant Chemotherapy and Organ-Preserving Surgery in Early Rectal Cancer
As reported in the Journal of Clinical Oncology by Hagen F. Kennecke, MD, MHA, and colleagues, the Canadian Cancer Trials Group phase II NEO trial has shown that 3 months of neoadjuvant chemotherapy resulted in tumor downstaging and avoidance of radical surgery in a high proportion of patients with ...
Can Patients With Low-Risk Nasopharyngeal Cancer Be Treated Safely With Radiotherapy Alone?
Intensity-modulated radiation therapy (IMRT) alone may be considered an effective treatment option for “low-risk” T1–2N1 and T3N0 nasopharyngeal carcinoma, according to trial data presented by Jun Ma, MD, MS, Professor of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China,...
